Clinical trials in Senhora Da Hora – page 10

679 clinical trials in Senhora Da Hora, Portugal. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in PortugalEnsaios-Clinicos.pt

Senhora Da Hora at a glance

679

clinical trials

Research sites0

Quick filters

679 trials in Senhora Da Hora

Open in trial search

Non-small cell lung cancer+1

Recruiting

Study of trastuzumab deruxtecan with pembrolizumab versus platinum chemotherapy with pembrolizumab for patients with untreated HER2-positive non-small cell lung cancer

Registered drugNo placebo

Study of trastuzumab deruxtecan with pembrolizumab versus platinum chemotherapy with pembrolizumab for patients with untreated HER2-positive non-small cell lung cancer

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Ischaemic stroke

Recruiting

Study of alteplase and tenecteplase for intravenous thrombolysis in patients with ischemic stroke who are taking direct oral anticoagulants

Registered drugNo placebo

Study of alteplase and tenecteplase for intravenous thrombolysis in patients with ischemic stroke who are taking direct oral anticoagulants

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Alteplase
Sponsor:Insel Gruppe AG

Contact Research Centre

Pulmonary arterial hypertension

Recruiting

A study of LTP001 in combination with standard treatment for adults with pulmonary arterial hypertension

Investigational

A study of LTP001 in combination with standard treatment for adults with pulmonary arterial hypertension

Investigational

Portugal

Participants:18–64 years · 65+ years · Healthy volunteers
Substances:LTP001
Sponsor:Novartis Pharma AG

Contact Research Centre

Dry age-related macular degeneration

Recruiting

Study of ONL1204 eye injections to slow vision loss in patients with age-related macular degeneration and geographic atrophy

Investigational

Study of ONL1204 eye injections to slow vision loss in patients with age-related macular degeneration and geographic atrophy

Investigational

Portugal

Participants:18–64 years · 65+ years
Substances:Xelafaslatide
Sponsor:ONL Therapeutics Inc.

Contact Research Centre

Relapsing multiple sclerosis

Recruiting

Study comparing remibrutinib and ocrelizumab in patients with relapsing multiple sclerosis who switch from ocrelizumab treatment

Registered drugNo placebo

Study comparing remibrutinib and ocrelizumab in patients with relapsing multiple sclerosis who switch from ocrelizumab treatment

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Ocrelizumab
Sponsor:Novartis Pharma AG

Contact Research Centre

Colitis ulcerative+1

Recruiting

Long-term safety study of subcutaneous vedolizumab in children and adolescents with ulcerative colitis or Crohn's disease

Registered drugNo placebo

Long-term safety study of subcutaneous vedolizumab in children and adolescents with ulcerative colitis or Crohn's disease

Registered drugNo placebo

Portugal

Participants:0–17 years
Substances:Vedolizumab
Sponsor:Takeda Development Center Americas Inc.

Contact Research Centre

Irritable bowel syndrome

Recruiting

Study of Saccharomyces boulardii CNCM I-745 to treat symptoms in adults with non-constipated Irritable Bowel Syndrome

Registered drug

Study of Saccharomyces boulardii CNCM I-745 to treat symptoms in adults with non-constipated Irritable Bowel Syndrome

Registered drug

Portugal

Participants:18–64 years · 65+ years
Substances:Loperamide Hydrochloride
Sponsor:Biocodex

Contact Research Centre

Triple negative breast cancer

Recruiting

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Registered drugNo placebo

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Non-small cell lung cancer+2

Recruiting

Study of THIO and cemiplimab compared to chemotherapy in patients with advanced non-small cell lung cancer who have received two previous treatments

Registered drugNo placebo

Study of THIO and cemiplimab compared to chemotherapy in patients with advanced non-small cell lung cancer who have received two previous treatments

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Cemiplimab
Sponsor:Maia Biotechnology Inc.

Contact Research Centre

Cardiomyopathy

Recruiting

Study of Nucresiran in Adults with Transthyretin Amyloidosis with Cardiomyopathy to Evaluate its Effects on Survival and Heart Problems

Investigational

Study of Nucresiran in Adults with Transthyretin Amyloidosis with Cardiomyopathy to Evaluate its Effects on Survival and Heart Problems

Investigational

Portugal

Participants:18–64 years · 65+ years
Substances:Nucresiran
Sponsor:Alnylam Pharmaceuticals Inc.

Contact Research Centre

Plasma cell myeloma

Recruiting

Study comparing daratumumab, lenalidomide and dexamethasone followed by linvoseltamab versus continued initial treatment in newly diagnosed multiple myeloma patients

Registered drugNo placebo

Study comparing daratumumab, lenalidomide and dexamethasone followed by linvoseltamab versus continued initial treatment in newly diagnosed multiple myeloma patients

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Daratumumab
Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Contact Research Centre

Squamous cell carcinoma of head and neck

Recruiting

Study of ficerafusp alfa and pembrolizumab as first treatment for patients with PD-L1-positive recurrent or metastatic head and neck cancer

Registered drug

Study of ficerafusp alfa and pembrolizumab as first treatment for patients with PD-L1-positive recurrent or metastatic head and neck cancer

Registered drug

Portugal

Participants:18–64 years · 65+ years
Substances:Ficerafusp alfa
Sponsor:Bicara Therapeutics Inc.

Contact Research Centre

Other cities in Portugal

The busiest research cities in the country

All 47 cities in Portugal

Clinical research in Senhora Da Hora

What the registry says about research in the country

01 Neurology & Mental Health

Innovative research focusing on Alzheimer's disease and associated conditions, including studies on psychosis treatment and cognitive decline prevention. Multiple trials exploring migraine prevention with novel therapeutic approaches.

Alzheimer's Disease Management
Migraine Prevention
Multiple Sclerosis Treatment

Studies are evaluating both symptomatic relief and disease modification strategies.

02 Oncology

Comprehensive research in breast cancer treatments, particularly focusing on HR+/HER2- variants and innovative combination therapies. Advanced studies in non-small cell lung cancer exploring new treatment paradigms.

Breast Cancer Therapeutics
Lung Cancer Treatment
Head and Neck Cancer

Trials emphasize targeted therapies and immunotherapy approaches.

03 Respiratory Medicine

Groundbreaking research in severe asthma management and chronic rhinosinusitis. Studies evaluating new treatments for COPD with focus on long-term safety and efficacy.

Asthma Management
COPD Treatment
Rhinosinusitis Therapy

Emphasis on innovative inhaler combinations and targeted biological treatments.

Back to Portugal All countries